ArticleInternational dental journal2026
Malignant Transformation Risk in Patients With Oral Leukoplakia and Type 2 Diabetes Mellitus.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimsOral leukoplakia (OLK) is the most common oral potentially malignant disorder, with a malignant transformation rate of up to 9.8%. Type 2 diabetes mellitus (T2DM) is associated with increasing cancer risk. However, risk factors for malignant transformation in OLK-T2DM patients remain undefined. This study aimed to identify these factors and develop prediction models integrating glycaemic and clinical indicators.
methodsA retrospective nested case-control study was conducted in a real-world OLK-T2DM cohort (2013-2025). Cases (n = 55) with histologically confirmed malignant transformation to oral squamous cell carcinoma were matched 1:2 by age and sex with controls (n = 110) without transformation. Glycaemic control (fasting plasma glucose [FPG], haemoglobin A1c [HbA1c]) was the main exposure. Risk factors were analysed using univariable analyses, multivariable conditional logistic regression, multivariable stratified Cox regression models and machine learning models.
resultsSuboptimal glycaemic control (HbA1c > 7% or FPG > 7.2 mmol/L) was strongly associated with malignant transformation, with each 1 mmol/L increase in FPG raising malignant transformation risk by 60% to 174% according to the results of multivariable stratified Cox regression models for the risk of malignant transformation. Moderate and severe oral epithelial dysplasia (adjusted hazard ratio = 399.43, P = .021) was also an independent predictor. By integrating glycaemic and clinical indicators, machine learning models achieved stable predictive performance (area under the receiver operating characteristic curve up to 0.78; accuracy up to 76.91%).
conclusionSuboptimal glycaemic control was independently associated with increased malignant transformation risk in OLK-T2DM patients after adjustment for key confounders. This association was consistent across both regression and machine learning models. CLINICAL RELEVANCE: These findings underscore the importance of early monitoring and strict glycaemic management, and suggest that incorporating glycaemic indicators into risk prediction tools may help improve the identification and management of high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.